Radius Health Inc (NASDAQ:RDUS) shares were up 9.4% on Tuesday . The stock traded as high as $20.19 and last traded at $20.09, approximately 844,076 shares traded hands during mid-day trading. An increase of 50% from the average daily volume of 563,308 shares. The stock had previously closed at $18.36.
A number of brokerages recently weighed in on RDUS. Leerink Swann reduced their target price on Radius Health from $49.00 to $35.00 and set an “outperform” rating on the stock in a report on Wednesday, November 6th. BidaskClub lowered Radius Health from a “hold” rating to a “sell” rating in a research note on Friday, January 3rd. ValuEngine lowered Radius Health from a “hold” rating to a “sell” rating in a research note on Friday. HC Wainwright restated a “hold” rating on shares of Radius Health in a report on Friday, December 20th. Finally, Royal Bank of Canada set a $27.00 price objective on Radius Health and gave the company a “hold” rating in a research note on Friday, November 1st. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and five have given a buy rating to the stock. Radius Health currently has an average rating of “Hold” and an average target price of $33.43.
The firm’s 50 day simple moving average is $21.20 and its 200-day simple moving average is $24.06. The company has a market capitalization of $847.68 million, a PE ratio of -4.12 and a beta of 0.72.
Radius Health (NASDAQ:RDUS) last issued its earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($0.65) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.80) by $0.15. The business had revenue of $46.77 million for the quarter, compared to the consensus estimate of $45.69 million. Radius Health had a negative net margin of 98.22% and a negative return on equity of 929.94%. The business’s revenue for the quarter was up 69.2% compared to the same quarter last year. During the same quarter last year, the firm posted ($1.09) EPS. On average, sell-side analysts predict that Radius Health Inc will post -3.12 EPS for the current fiscal year.
In related news, major shareholder Growth N. V. Biotech purchased 100,000 shares of the stock in a transaction that occurred on Wednesday, November 6th. The stock was purchased at an average cost of $23.00 per share, for a total transaction of $2,300,000.00. Following the acquisition, the insider now owns 6,881,685 shares in the company, valued at $158,278,755. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 4.00% of the stock is currently owned by corporate insiders.
Several institutional investors and hedge funds have recently modified their holdings of the business. Rhumbline Advisers grew its stake in shares of Radius Health by 1.3% in the third quarter. Rhumbline Advisers now owns 67,718 shares of the biopharmaceutical company’s stock valued at $1,744,000 after buying an additional 846 shares in the last quarter. California State Teachers Retirement System lifted its position in Radius Health by 1.5% during the 3rd quarter. California State Teachers Retirement System now owns 70,441 shares of the biopharmaceutical company’s stock worth $1,814,000 after acquiring an additional 1,060 shares in the last quarter. Captrust Financial Advisors acquired a new position in Radius Health during the 2nd quarter worth approximately $38,000. Metropolitan Life Insurance Co NY boosted its holdings in Radius Health by 14.0% in the 3rd quarter. Metropolitan Life Insurance Co NY now owns 15,451 shares of the biopharmaceutical company’s stock worth $398,000 after acquiring an additional 1,902 shares during the period. Finally, Ladenburg Thalmann Financial Services Inc. boosted its holdings in Radius Health by 3,130.7% in the 2nd quarter. Ladenburg Thalmann Financial Services Inc. now owns 2,423 shares of the biopharmaceutical company’s stock worth $59,000 after acquiring an additional 2,348 shares during the period.
About Radius Health (NASDAQ:RDUS)
Radius Health, Inc, a biopharmaceutical company, develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology. The company markets TYMLOS for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide transdermal patch, a short-wear-time patch formulation of abaloparatide to treat postmenopausal women with osteoporosis; RAD1901, a selective estrogen receptor down-regulator for the treatment of metastatic breast cancer; and RAD140, a non-steroidal selective androgen receptor modulator to treat breast cancer.
Read More: Price to Earnings Ratio (PE) Basics
Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.